Vivesto

Vivesto is a Swedish company developing cancer medicines, listed in Stockholm. Its human medicine Cantrixil is being developed for blood cancer and has orphan drug status in the United States for acute myeloid leukaemia.

Also called: Vivesto AB

Vivesto AB, based in Solna, Sweden, describes itself as a drug development company for hard-to-treat cancers; its shares trade on Nasdaq Stockholm under the ticker VIVE. Its portfolio is Cantrixil, being developed for blood cancers, and the veterinary oncology programme Paccal Vet (paclitaxel micellar), in a pilot trial in dogs with splenic haemangiosarcoma and a dose-finding study in cats. On 1 November 2026 the FDA granted orphan drug designation to Cantrixil for acute myeloid leukaemia; the company announced it on 3 November 2026 and said it is working towards a phase 1 study in AML. The FDA had designated Cantrixil for ovarian cancer in 2015.

Headquarters

Solna, SE

Scorecard

All companies

#697of 1706 companies, score 4

modalities +2
24-month regulatory events +2

0 approved, 0 in phase 3, 0 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.

Type

Biotech · VIVE

Stage

Public

Website

www.vivesto.com/en/

Products

PreclinicalSmall molecule (cyclodextrin formulation)

Cantrixil

Cantrixil is an experimental medicine from Vivesto being developed for blood cancers. It is at the laboratory stage for acute myeloid leukaemia, where the FDA has given it orphan drug status, after an earlier phase 1 study.